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Abstract: The Stabilin receptors are a two-member family in the type H class of scavenger receptors.
These dynamic receptors bind and internalize multiple ligands from the cell surface for the purpose
of clearing extracellular material including some synthetic drugs and for sensing the external
environment of the cell. Stabilin-1 was the first receptor to be cloned, though the biological activity
of Hyaluronic Acid Receptor for Endocytosis (HARE)/Stabilin-2 was observed about 10 years prior
to the cloning of Stabilin-1. Stabilin-1 has a more diverse expression profile among the tissues than
HARE/Stabilin-2. This review will focus on HARE/Stabilin-2 and its interactions with hyaluronan,
heparin, and phosphorothioate antisense oligonucleotides and what is known about how this receptor
participates in signaling upon ligand binding.
Keywords: stabilin; HARE; receptor-mediated endocytosis; scavenger receptor; hyaluronan
1. Initial Discovery
The discovery of the cloned Stabilin receptors began with Stabilin-1 in the early 1990s.
A monoclonal antibody raised against whole human spleen homogenate produced a monoclonal
antibody (MS-1) against an antigen that was initially identified as a large protein that is preferentially
expressed in the sinusoidal endothelia of spleen, lymph node, liver, and adrenal cortex [1]. The
identified MS-1 antigen is an inducible protein not found in normal skin lesions, but rather in diseased
skin and some cancers such as psoriasis, melanoma, and T-cell lymphomas. Induction of MS-1 antigen
is stimulated by Interleukin (IL)-4 and Dexamethasone and inhibited by tumor necrosis factor (TNF)-α,
IL-1β, and IL-6 [2] in cultured human peripheral blood monocytes [3,4]. The use of the MS-1 antibody
allowed for immunoprecipitation of the MS-1 antigen which was subjected to matrix-assisted laser
desorption ionization—time of flight (MALDI-TOF) analysis for protein identification. The same
authors used hyaluronic acid (HA) affinity chromatography to identify a similar protein that bound
HA with a high degree of topology between both receptors [3]. However, several years prior to the
publication of Politz et al. [3], the rat HA-binding receptor was discovered from rat liver sinusoidal
endothelial cells (SEC HA receptor) [5,6] and identified as the primary HA turnover receptor named
HARE (Hyaluronic Acid Receptor for Endocytosis) [7]. Due to their topological similarity, the receptors
that were formerly named MS-1 antigen or protein, FEEL-1, CLEVER-1 and FEEL-2, HARE are now
almost universally recognized as Stabilin-1 and Stabilin-2, respectively [3,8,9] (Figure 1 as annotated
by [10,11]). Although there was a bit of confusion as to the number of protein subunits composing these
receptors during their initial characterization [1,7,12], cloning and expression in stable cell lines have
confirmed that Stabilin-1 is a monomer with two forms expressed as a tight doublet at about 320 kDa by
sodium dodecyl sulfate—polyacrylamide gel electrophoresis (SDS-PAGE) [13] and a possible smaller
isoform at around 140 kDa by SDS-PAGE which has not been confirmed by other sources [14]. Human
Stabilin-2 is expressed as two monomers or isoforms at 315-kDa and 190-kDa by SDS-PAGE [15]
(Figure 2) which is similar to rat Stabilin-2 expressed as 300-kDa and 175-kDa isoforms [7]. Both human
and rat receptors have nearly the same number of amino acids but the higher mass of the human
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receptor is solely contributed by post-translational glycosylation of the receptor. In native SECs, the
ratio of the large to small isoforms is close to a 1:1 ratio in liver, whereas in the spleen, it is 2:1 or 3:1 [7].
However, in stable cell lines, the isoform ratio is closer to 8–10:1, suggesting that the mechanism for
the appearance of the 190HARE is more robust in primary cells [15]. It is thought that these isoforms
are a product of proteolytic cleavage that occurs somewhere between the trans-Golgi network and
the plasma membrane during synthesis. Using [35S] labeled tracking, the appearance of the small
isoform appeared immediately after the large isoform was fully glycosylated (unpublished data). For
simplicity in nomenclature, the large isoform of Stabilin-2 will be referred to as Stabilin-2 and the
smaller isoform of the same receptor will be referred to as the 190HARE.
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Figure 1. Topology of Stabilin-1 and Stabilin-2. The overall topologies of human Stabilin-1 and
human Stabilin-2, including the 190HARE, are very similar with an overall protein sequence identity of
39% and similarity of 56% between the two large receptors. The topology algorithm was derived using
the SMART program and the homology was calculated using BLAST program of the National Center
for Biotechnology Information.
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Figure 2. Protein characterization by SDS-PAGE. Stable cell lines expressing human (1) 190HARE,
(2) Stabilin-2 or 315HARE, and (3) Stabilin-1 were prepared as whole cell lysates and 20 µg of lysates
were separated by 5% denaturing gel electrophoresis without reduction. The dark arrowhead (315 kDa)
indicates the monomer of Stabilin-2 and doublet of Stabilin-1 and the open arrowhead (190 kDa)
indicates the presence of the 190HARE in cell lysates expressing a construct that only codes for the
190HARE and Stabilin-2. All plasmid co structs (pcDNA5/FRT/V5-6xHis, I vitrogen, Carlsba , CA)
used to express these proteins co t ined the cytom gal virus promoter f r protein expression and
C-terminal tags, 6xHis and V5. Anti-V5 antibody was used to detect the recombinant protein followed
by a secondary antibody for standard colorimetric detection with alkaline phosphatase.
2. Tissue Expression
The location of expression determines functionality, especially with receptors that bind to multiple
ligands. One of the first studies for rat 175HARE expression was performed by Zhou et al. in
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which crude tissue extracts were produced in Nonidet NP-40 from spleen, lung, small intestine, large
intestine, muscle, kidney, heart, brain, and liver. The protein was immunopurified by a monoclonal
antibody bound to sepharose beads against rat Stabilin-2 and then separated on a 5% acrylamide gel
for SDS-PAGE and probed with mAb-235 against rat 175HARE and radiolabeled HA. These results
indicated that Stabilin-2 was only expressed in liver and spleen tissues and the ratio of the isoforms
varied between these two tissues [7]. Later work published from the same laboratory confirmed by
histological staining that the sinusoids of liver, medullary sinuses of lymph node, and venous sinuses
of spleen were enriched in Stabilin-2 expression [16].
One year after the initial publication, Politz et al. used Northern blots to confirm the expression
of both human Stabilin-1 and Stabilin-2. This expanded the known tissues for these two receptors
where Stabilin-2 expression was strong and verified in liver, spleen, lymph node with much lighter
expression in heart, placenta, skeletal muscle, pancreas, thymus, and bone marrow [3]. Stabilin-1 had
strong expression in placenta, liver, spleen, and lymph node with lighter expression in peripheral
blood leukocytes [3]. A year after this publication, Falkowski et al. took a closer look using
immunohistochemistry using an antibody raised against a Stabilin-2 peptide and detected mouse
Stabilin-2 expression in tissues that were negative for expression in previous work. Expression
was specifically in the ocular corneal epithelium, ocular cuboidal epithelium, cardiac mensenchyme,
brain ependymal/cuboidal epithelial cells lining the ventricles, and the epithelial cells of the renal
papillae [17]. It is understandable that these were missed previously as these tissues have only a single
cell layer expressing the receptor that would easily get diluted out in a whole-tissue homogenate.
Recently, Stabilin-2 expression was found in myoblasts and contributes, in part, to their fusion during
differentiation or regeneration [18]. Current online genomic databases such as http://gtexportal.org/
home are also helpful in determining Stabilin expression throughout many tissues, but results should
be interpreted cautiously as transcriptomic data is fully correlative for protein expression [19,20].
3. Hyaluronan Binding and Endocytosis
Hyaluronan (HA) is a very long polymer containing disaccharides composed of glucuronic
acid β1-3 linked to N-acetylglucosamine and these disaccharides are linked by β1-4 glycosidic
bonds. HA is a necessary extracellular matrix molecule essential for a wide variety of functions
including joint health and lubrication, ocular integrity, skin hydration, fertility, cancer metastasis,
and many more physiological functions [21–25]. Likewise, turnover of HA is very dynamic in which
hyaluronidases/spreading factor/mechanical forces/oxidative stress break down very large HA in the
tissues which then drains into the lymphatics and finally into the blood [26]. It is the function of
clearance receptors in the lymphatics and circulatory systems to maintain low levels of HA in these
fluids. Early studies of HA metabolism reveal that [3H]Hyaluronan injected via the marginal ear vein of
a mature rabbit is rapidly cleared in about 20 min from plasma with a half-life of 3.5–6 min [27]. Tissue
accumulation of [3H]Hyaluronan was primarily in liver, spleen, lymph nodes, and bone marrow, all
tissues containing high expression levels of Stabilin-2 with large overlaps in Stabilin-1 expression [28].
Furthermore, the liver SECs, and not the Kupffer or hepatocytes, have the highest accumulation of
hyaluronan [29]. Both Stabilin-1 and Stabilin-2 are highly expressed in liver SECs among other tissues
previously mentioned. Although both Stabilins contain X-Link domains, the Stabilin-1 domain is
inactive for hyaluronan binding [3], thus Stabilin-2 is the primary scavenger receptor for systemic HA.
To investigate the HA–Stabilin-2 interaction more closely and in detail, we expressed the human
190HARE (smaller isoform) in Flp-In HEK 293 cells [30]. Using a variety of techniques including HA
degradation monitoring, Scatchard analysis, and internalization vs binding assays, the disassociation
rate (kD) for the 190HARE was calculated to be 7.2 nM which was similar to the kD in recombinant
SK-Hep-1 cells expressing the rat 175HARE at 4.1 nM [31]. In addition, the 190HARE recycling time on
the cell surface was 7–9 min which was also similar to what had been calculated for recycling time for
native rat Stabilin-2 receptors in primary liver SECs [32]. These physical properties revealed that the
recombinant 190HARE was a good model for the native Stabilin-2 receptors in SECs, a cell type that
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is difficult to culture and maintain its differentiation for more than two days. Full-length Stabilin-2
was also expressed in stable cell lines under the same promoter and cell type as the 190HARE. For
reasons unknown, the expression level of Stabilin-2 was always robust, but significantly lower than
the 190HARE. In addition, the 190HARE was always co-expressed with Stabilin-2 in these cell lines,
suggesting that production of the small isoform is a natural byproduct of the full-length receptor.
Endocytosis of HA in the Stabilin-2 cells was not significantly different from the 190HARE when
accounting for the number of cells and receptor expression levels. Expressing both isoforms as soluble
ecto-domains and purifying them by nickel chelate chromatography revealed that the binding of
HA in an ELISA-like format for both receptors was nearly equivalent (20.7 ± 6.4 nM for 190-HARE,
9.9 ± 1.2 nM for Stabilin-2) [15], further demonstrating that the binding occurs primarily within the
X-Link domain and not in other areas of the receptor. X-Link binding of HA was further confirmed in
cells expressing a receptor without the X-Link domain as these cells were not able to internalize any
[125]I-HA [33]. Curiously, expression of the Stabilin-2 ecto-domain did not result in producing a small
isoform, indicating that membrane attachment is required for small isoform (190HARE) expression
(Figure 3).
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Figure 3. Membrane attachment is required for production of 190HARE. Cells expressing either
315HARE (Stab lin-2) or secreted 315HARE (lacking the transmembrane and cytoplasmic domains)
were lysed i iti e medium and im unoprecip tated with Ab30 conjugated o sepharose beads.
Immunoprecipitated proteins from (1) cell lysate from both 315HARE and s315HARE were mixed 1:1,
(2) s3 5HARE lyste, and (3) 315HARE lysate were eparated by 5% SDS-PAGE on a 20 cm gel, blotted,
and probed with anti-V5 antibody for protein detection.
The X-Link domain of Stabilin-2 has the highest homology to another well-known hyalectin,
tumor necrosis factor inducible gene 6 protein (TSG-6), a protein whose expression is induced by
inflammatory mediators, growth factors, ovulation inducers, and matrix remodeling [34–36]. In silico
modeling based on the structural ork perfor ed ith TS -6 reveals that A binds within a groove of
the X-Link domain and interacts directly with tyrosine residues through hydrogen bonding [37]. This
TSG-6 model has been upgraded more recently to reflect the more intimate interaction of HA with the
X-Link domain in which binding is mediated with a combination of ring stacking interactions, hydrogen
bonds, salt bridges, and hydrophobic interactions along the binding groove [38]. The similarity of HA
binding with TSG-6 and the 190HARE was further corroborated by another independent study using
atomic force microscopy (AFM) to determine the bond strength between HA and several hyalectins.
Using biotinylated HA at the tip of the AFM probe and proteins bound to solid substratum, the mean
rupture force could be calculated between a single polymer of HA and the hyalectin. Both TSG-6 and
190HARE had a mean rupture force with HA at 24 and 25 picoNewtons (pN), respectively, further
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suggesting that both proteins interact with HA in a similar fashion. Comparatively, HA rupture forces
were 34 pN for CD44, 37 pN for versican, and more than 52 pN for aggrecan X-Link domains [39].
Although the binding affinity of HA for 190HARE is in the low nanomolar range, the bond strength
with which it binds is one of the weakest among the hyalectin family. Biologically, this is logical as this
is a constitutively recycling receptor that must bind HA with high specificity and then release this
cargo in the endosomes. The other hyalectins with higher rupture forces are all HA-binding proteins
for structural purposes, hence the more stable interactions.
Data derived from cell models suggests that the degradation of internalized HA does occur, though
this is highly dependent on the cell type. For example, SK-Hep-1 cells are of endothelial origin [40], but
are very active in transcytosis. It is estimated that about half of the HA that is internalized by SK-Hep-1
cells stably expressing the rat 175HARE is delivered back to the extracellular space entirely intact [41].
In 190HARE cells (HEK293 background), most of the HA is degraded and the ratio of intact versus
degraded HA may be measured by cetylpryridinium chloride precipitation [41,42]. Primary SECs
have a much greater capacity for endocytosis and degradation of HA than these stable recombinant
cell models. HA is internalized by Stabilin-2/HARE and transported to lysosomes which contain
lysosomal β-glucuronidases, β-N-acetylglucoaminidase, and hyaluronidases for polymer degradation.
The HA polymer is degraded into monosaccharides that are transferred to the cytosol where glucuronic
acid is converted by isomerases for metabolism. The N-acetylglucosamine is also transferred to the
cytoplasm and phosphorylated then deacetylated for the eventual formation of acetate, lactate, and
fructose [42–44].
4. Heparin Clearance by Stabilin-1 and Stabilin-2
Heparin is a complex polysaccharide made up of two base sugars, N-acetylglucosamine and
glucuronic (epimer: iduronic) acid. These two sugars may be modified in the Golgi of the cell to give
rise to up to 32 different disaccharide combinations resulting in more than 100 trillion unique heparin
polymers [45]. The heparin core protein is Serglycin which is enriched in serine and glycine residues in
which the serine is modified with the heparin polymer. As a post-translational product of Serglycin,
the first modifications occur in the ER and a step-wise process of elongation and modification to
the sugar chain occurs in the Golgi [46]. Heparin is produced in mast cells of the immune system
which are enriched in the gut mucosa of mammals [47]. Heparin was discovered in 1916 by a medical
student, Jay McLean, working in the laboratory of Professor Howell, and its use as an anticoagulant
in medical applications began in the mid-1930s [48]. Three forms of heparin for use in medicine are:
purified unfractionated heparin (UFH) with a mass average of 13.5 kDa, the processed UFH in the
development of low-molecular-weight heparin (LMWH) with a mass average of 3.5 kDa, and the
synthetic pentasaccharide, Fondaparinux [49].
Regardless of the route of administration, heparin clearance from circulation is dependent on
the liver and kidneys. Longer polymers tend to be taken up by the liver for degradation and then
undergo filtration by the kidney. It was discovered that the SECs of the liver are the primary site for
heparin clearance from blood [50,51]. The primary, though not only, receptor for heparin clearance
was discovered to be Stabilin-2 using direct binding methods of purified protein with radioactively
labeled heparin [52]. Heparin has a high electronegative charge and, thus, it is a “sticky” molecule
that binds to many components on the surface of cells. Cells that do not express Stabilin-2 will slowly
internalize heparin during the process of normal membrane turnover. However, cells that do express
either Stabilin-2 or 190HARE take up much more heparin compared to the same type of cells that do
not express these receptors. Both UFH and LMWH are taken up by Stabilin-2 [49] and Stabilin-1 is also
involved with heparin binding and endocytosis [53].
As previously mentioned, heparin is a very heterogeneous molecule with respect to both size
and modification. Currently, therapeutic heparin is a natural product that comes from swine gut
mucosa from which it is purified and refined [54,55]. The goal of making synthetic heparin has been
around for decades [56,57] and is currently becoming a reality with the development and refinement
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of chemoenzymatic processes [58–62]. Using homogenous synthetic heparin polymers, we have
found that the heparin polymer needs to be sulfated for binding with Stabilin-1 or Stabilin-2. The
nonsulfated polymer, heparosan, does not interact with the Stabilin clearance receptors and may be
a good candidate as a vehicle for drug delivery [63,64]. The minimal binding requirement is for the
polymer to be at least 10 sugars long and the presence of the 3-O sulfate increases binding affinity at
least fivefold [53]. To determine how important the 3-O sulfate is for overall metabolism and uptake in
the liver, we subcutaneously injected mice with physiological doses of dodecamers (12mers) with or
without a single 3-O sulfation residue (15 vs. 14 total sulfate groups along a single dodecamer). The
3-O sulfate routed the polymers through the liver for endocytosis and degradation and also increased
the half-life of the 12mer in blood. Without the 3-O sulfation, the polymer had a far higher chance of
getting immediately filtered by the kidneys [65]. From these experiments, we deducted that polymer
charge is not the only defining characteristic of heparin–Stabilin interactions. The orientation of the
charge is just as important as the charge itself for optimal binding with the receptor. The single 3-O
modification along the polymer affected affinity to Stabilin-2 and liver, increased the half-life in blood,
and, possibly, allowed interaction of heparin with other blood components. It is clear that the Stabilin-2
receptor directly affects the half-life of systemic UFH and LMWH.
The precise location of where heparin binds with the Stabilin-2 receptor is not known and the
primary sequence of the amino acids does not reveal an obvious cluster of positively charged amino
acids that are common for many heparin binding proteins. Since both Stabilin-2 and 190HARE
bind with heparin with the same affinity [52], the putative binding site(s) are only in the 190HARE
sequence and the N-terminal half of Stabilin-2 does not contribute to binding, despite similar domain
organization (Figure 1). Stabilin-2 (and Stabilin-1) are both extensively folded and it is hypothesized
that a heparin binding domain/groove is formed as distal amino acids are brought together in close
proximity to form this site. Unfolding of the receptor through reduction of the disulfide bonds renders
the receptor unable to bind any ligands.
Heparin does not interfere with HA binding on Stabilin-2. In the TSG-6 model, the X-Link
domain may bind either HA or heparin, but not both together at two different binding sites within the
module [66]. In contrast, heparin binds to a distal site on Stabilin-2 and not within the X-Link domain.
Thus, both HA and heparin may bind with Stabilin-2 simultaneously [67].
5. Stabilin Interactions with Antisense Oligonucleotides (ASOs)
Antisense oligonucleotides are chemically synthesized oligonucleotides that bind RNA through
Watson–Crick base pairing and mediate its destruction via endogenous enzymes such as Dicer and
RNase H [68,69]. These therapeutic drugs are specific for their targets owing to the nucleotide sequence
and have relatively few side effects. ASOs are resistant to degradation due to the altered synthetic
chemistry of the backbone in which the phosphodiester is substituted for a phosphorothioate (PS)
or phosphorodiamidate chemistry which is resistant to nucleases (Figure 4). In addition, the 2′
position of the ribose may be modified with any number of chemistries such as a methoxyethyl (MOE),
fluro, O-methyl (OMe), and other chemistries to enhance stability and facilitate binding to target
RNAs [70]. The chemistry for specificity and stability is well known, however, delivery to the correct
tissues has been challenging [70]. Many advancements in the past five years have begun to solve
this issue by conjugating ASOs with targeting ligands such as N-acetylgalactosamine for targeting
the liver parenchyma [71] and the GLP1 peptide for targeting the pancreas [72]. Other delivery
methods include encapsulating the ASO with lipid-based molecules to form a nanoparticle comprising
phosphatidylcholine, cholesterol, polyethylene glycols, and amino lipids for delivery by blood infusion.
The use of naked or gymnotic delivery methods utilizes the backbone chemistry for subcutaneous and
intrathecal administration in which the phosphorothioate chemistry is the most popular as it sticks to
cellular surface membranes and proteins for eventual internalization [73].
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Only a few receptors are known to internalize phosphorothioate-based (PS) ASOs and they are
the asialoglyoprotein receptor (ASGPR) [74], scavenger receptor A (SR-A) [75], epidermal growth
factor rec t ) [76], and the Stabilins [77]. Of this group, the Stabilins have the hig st affinity,
avidity, an turnover rate in comparis n with the others, thus, the Stabilins are the primary clear nce
mechanism for the PS-ASOs due to thes prop rties and their location f expression. Using a 5-10-5
MOE-flanked, single-stranded PS-ASO that was iodinated with [125I], it was found that there was no
competition w h HA binding 315HARE cells. Th re was parti l competition with heparin, however,
and it is not known at this time wheth r t a is due to competition for the same binding site on the
receptor or at a secondary site wh ch affects ligands at the primary binding site [77].
Since ASOs may be synthesized with a wide variety of chemistries, we asked which chemistries
are the best ligands for the Stabilins. In Miller et al., we used an iodinated single-stranded 5-10-5 MOE
fully PS gapmer as the probe and competed it with a 2 0-fold concentration of a variety of ASOs of
different lengths t PS- S bound to the secreted ecto-domain of
the 190HARE (s190HARE) in an enzyme-linked im unos rbent ass y (ELISA)-like ass y t 140 nM.
The results show that as the number of flanking residues decrease in number, so does the competi ion
with the 20mer ASO. Using a fluorescence p larization assay, we determined that a full PS oligo has
the highest affinity for s190HARE which decreases as PO sidues are substituted in. Modifications
of the 2′ ribose has very little effect on S abilin binding nd the ucleotide sequenc has no effect on
binding. Single-stranded oli os have a much higher avidity for t Stabil ns than double-stranded
oligos. I is thought that the double-stranded oligo is more rigi and interactions between the oligo and
the Stabilins need to be flexi le to accommodate th interactions of the anionic sulfur atom with the
protein surface [70,78]. Knowing that the avidity of the ligands may be modulat d by manipulating
the number and spacing of PS r sidues, it is possible to increase or decrease the half-life of the ASO in
blood, thereby exposing other tissues for either longer or sh rt r times to the ASO.
An independent genome-wide association study using a hybrid mouse diversity panel confirmed
that Stabilin-2 a vesicle-associated membr ne pro ein 3 (Vamp3) are closely associated w h hepatic
ASO d position in more than 100 geneti ally unique strains f mice [79]. Throughout this work, it
was confirmed that (i) mice strains wit lower Stab2 expression contained significantly lower hepatic
PS-ASO accumulation,(ii) immunohistochemistry of liver sections confirmed that the SECs of the
liv were a site of high PS-ASO accumulation, and (iii) Stab2-/- mice ac umulated a significantly
lower amount of ASOs in their liver and spleen. What was surprising in this work was that efficacy
of ASO-mediated knockdown in the liver of WT and Stab2-/- mice was similar, leading to the idea
that initial uptake is front-loading the nonproductive pathway and that low amounts of ASOs are
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very effective at mRNA suppression. ASO accumulation was primarily in the SECs, though the gene
of interest targeted by the ASO was in the hepatocytes. More work needs to be done on how the
architecture of the liver with differential scavenger receptor expression affects the distribution and
efficacy of ASOs.
The Stabilin receptors are only one piece of the endocytosis machinery involved with PS-ASO
uptake. Since there is a weak correlation between uptake and efficacy in the GWAS study, it is
hypothesized that there are several ASO endocytosis mechanisms and each of these pathways have
varying levels of ASO efficacy. Using a screen for several common markers for early and late
endocytosis-related proteins, we found that Rab5C, and not Rab5A or Rab5B, is essential for productive
uptake of an ASO targeting malat-1 in 190HARE cells [80]. “Productive uptake” in this context means
that the ASO was internalized and efficiently knocked down its target RNA. Another study led by
Astrazeneca came to these same conclusions about Rab5C in a screen with several cancer cell lines using
an ASO targeting KRAS [81]. Even though the Stabilins were not expressed in these cell lines, Rab5C
was a major determinant for productive uptake. It is not yet known if Stabilin-2 and Rab5C interact
directly or are just associated with the same early endosomal machinery/vesicles. Clearly, Stabilin-2 is
directly involved with tissue accumulation of the PS-ASOs, though how this affects both short- and
long-term efficacy of the PS-ASO in the background of multiple mechanisms of internalization still
needs to be determined.
6. Receptor Signaling
Although the ecto-domains of Stabilin-1 and Stabilin-2 exhibit high homology, the cytoplasmic
domains (consisting of 4% of the receptor) are very diverse and show no homology. To date, few
signaling studies have been performed for Stabilin-1 [82], therefore, this section will only focus on the
progress made with 190HARE. The investigation into whether the Stab2/190-HARE receptor performs
any downstream signaling to modulate cell behavior was to determine if cells are responsive to
specific ligands through this receptor. With the use of anti-phosphotyrosine antibodies and confirmed
with Pro-Q Diamond (Life Technologies) protein staining, it was determined that the 190HARE and
315HARE (Stabilin-2) receptors are phosphorylated in a time-responsive manner in response to 10 µg of
(~250 kDa or 40 nM) HA. For each 190HARE cell line, phospho-ERK1/2, and not JNK or p38 signaling,
increased up to 30 min and then rapidly lost the signal by 45 min. The HA response was confirmed
by repeating some of the key experiments in cells expressing the 190HARE lacking the Link domain
(190-HARE∆Link), suggesting that when HA binds to the receptor, the receptor propagates a signal via
the mitogen-activated ERK kinases [33]. Phosphorylation of residues within the cytoplasmic domain
was predicted to four amino acids (Ser2497, Ser2537, Tyr2519, and Tyr2531) with the NetPhos 2.0 program.
Endocytic receptors often contain one or more specific domains that facilitate entry of the receptor
in the forming endosome. The 190HARE cytoplasmic domain contains five endocytic domains with
two that significantly overlap, technically forming a single motif adjacent to the transmembrane
domain (Figure 5, underlined). Are all four of these domains essential for receptor function in terms
of cycling through the endocytic pathway and ligand uptake or is there some redundancy in their
functions? Using site-directed mutagenesis, expression levels and HA binding of the mutant 190-HARE
receptor did not differ significantly from the WT 190HARE. However, the deletion of the first three
domains (M1-M3) reduced endocytosis of HA by about 50% with the mutant lacking Tyr2519 the most
severely affected. Double- and triple-deletion mutants were made to zero in on the significance of
the redundancy of these motifs and a triple mutant lacking M1,M2, and M4 while retaining Tyr2519
reduced endocytosis by 42%, while the same triple mutant that was lacking Tyr2519 had a reduction of
HA uptake of 95% when compared to WT [83]. Interestingly, swapping only the Tyr2519 to alanine had
only a 5% reduction in endocytosis of HA, suggesting that efficient ligand uptake, receptor routing
through the cell, ligand delivery to lysosomes, and recycling of the receptor to the membrane surface is
a coordinated effort utilized by all four motifs of 190HARE [83].
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activity for HA of different sizes [85]. In addition, the liver SEC which is located at the interface of the
liver parenchyma and blood circulation plays an active role in maintaining homeostasis. It is thought
that this cell type of the liver promotes an anti-inflammatory and antifibrotic environment during early
stages of non-alcohol fatty liver disease [90]. The mechanism for doing this lies in the receptors that
are expressed at the cell surface and both Stabilins are robustly expressed in these cells of the liver.
7. Conclusions/Perspectives
The Stabilins are an enigmatic receptor family in which their entire coordinated physiological
functions are still not well understood. How does a receptor bind multiple ligands and know how
to propagate signal transduction based on the ligand? What is the relationship of the isoforms of
Stabilin-2 to each other and with Stabilin-1 when expressed within the same cell? Though there have
been multiple splice variants of Stabilin-2 discovered on the transcript level [20], are these proteins
translated and expressed by their respective tissues? What is the overall physical structure of each
receptor and how does that relate to their respective functions? These and other questions still need to
be addressed in order to understand the biochemical and physiological role of each Stabilin receptor.
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